Why Neogen Is Up 102% Even Though It Swung To A Loss

If Neogen sat on your watchlist instead of in your portfolio, the move over the past year may feel like a missed call. Holding Neogen over the past year would have returned 102.4%, including dividends. That outcome invites a tougher question. Back on 27 October 2025, could stronger digital testing adoption and rising protein demand have reasonably signalled that regulatory driven food safety and animal diagnostics revenue might scale faster than the market was assuming?

Neogen has already moved. Pinpoint other ways to investigate the theme among 34 healthcare AI stocks.

The Two Stories Investors Had To Weigh On Neogen

Neogen shares cost US$6.21 at the start of the period, and investors were really choosing between two very different stories about how digital testing, regulation, and protein demand might play out.

The bullish view put Fair Value at US$8, a rough guide to what the price could be if revenue fell 1.1% a year yet profit margin reached 12.3% and the stock later traded on a 21.2x P/E.

The cautious narrative pointed to Fair Value of US$5, assuming revenue declined 1.5% annually, profit margin moved to 12.5%, and persistent integration issues and tariffs kept the multiple nearer 13.2x.

What The Neogen Evidence Put To The Test

The clearest data point for Neogen was Q1 2027 revenue of US$222.8 million compared with US$209.2 million a year earlier, which leaned toward the optimistic case that testing demand could build. The story on profitability pulled the other way. Net income swung from a US$36.3 million profit to an US$11.9 million loss, and net margin moved from 17.4% to a loss of 5.3%, so the profitability leg of the bullish thesis stayed unproven. Overall, the evidence cut both ways.

The hinge assumption here was that higher Food Safety and Animal Safety volumes would eventually support healthier earnings. When you assess another diagnostics group, track revenue against net margin over several reports and test whether rising top line is actually turning into sustained cash earnings rather than just higher sales.

What Neogen's Run Leaves You Paying For Today

Neogen now trades at US$12.47 after a 102.4% gain over the past year, and the selected Narrative places its Fair Value above that level rather than below it.

The Narrative rests on Neogen turning capacity, consumables and efficiency projects into stronger cash economics, and argues today’s price still does not fully credit sustained quality control alongside higher margin conversion.

"The main thing that has to go right is that Neogen converts its expanded production capacity, higher consumable usage, and efficiency gains into the higher gross margin, EBITDA margin, and free cash flow conversion targets management has set for 2031, while maintaining product quality and compliance."

Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there

Neogen And A Different Kind Of Data

Neogen highlights how digital testing can reshape what quality control looks like. Nearby, another business focuses on surgical decisions rather than food.

Here the crucial input is not reagents or swabs. Surgeons need detailed, real time information about their own procedures and technique.

This company builds robotic systems that turn operations into data. Hospitals then use connected tools to review performance and track how surgeons change practice.

Neogen users study tests and thresholds. A similar mindset can apply to operating rooms, where a robotic platform and its digital ecosystem turn precision into something measurable and comparable.

One Narrative has already put a figure on it. → Uncover the company trading 16% below one Narrative's Fair Value

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com